<code id='AD7461F878'></code><style id='AD7461F878'></style>
    • <acronym id='AD7461F878'></acronym>
      <center id='AD7461F878'><center id='AD7461F878'><tfoot id='AD7461F878'></tfoot></center><abbr id='AD7461F878'><dir id='AD7461F878'><tfoot id='AD7461F878'></tfoot><noframes id='AD7461F878'>

    • <optgroup id='AD7461F878'><strike id='AD7461F878'><sup id='AD7461F878'></sup></strike><code id='AD7461F878'></code></optgroup>
        1. <b id='AD7461F878'><label id='AD7461F878'><select id='AD7461F878'><dt id='AD7461F878'><span id='AD7461F878'></span></dt></select></label></b><u id='AD7461F878'></u>
          <i id='AD7461F878'><strike id='AD7461F878'><tt id='AD7461F878'><pre id='AD7461F878'></pre></tt></strike></i>

          Home / entertainment / entertainment

          entertainment


          entertainment

          author:entertainment    Page View:55
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In